Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab consolidation in stage III NSCLC
NCT05414630Phase 2Unknown
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Status: unknown.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05414630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414630.